Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer

Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer
复制标题

DOI:
10.1007/s10552-019-01195-x
复制
发表时间:
2019-08-01
影响因子:
2.3
通讯作者:
Auvinen, A.
Auvinen, A.
中科院分区:
医学4区
文献类型:
--
作者:
Kinnunen, P. T. T.;Murtola, T. J.;Auvinen, A.

文献摘要

被引文献

相似文献

目的抗凝剂可降低癌症患者的死亡率,但证据仍有争议。我们研究了不同的抗凝剂和癌症death.MethodsAll抗凝剂的使用在1995年至2015年之间的相关性进行了分析75,336名男性在芬兰随机研究筛查前列腺癌。排除了患有流行性癌症的男性。进行多变量考克斯回归,以比较(1)抗凝剂使用者总体和(2)华法林使用者与抗凝剂非使用者之间以及(3)华法林或(4)低分子量肝素(LMWH)与其他抗凝剂使用者之间任何癌症死亡和9种特定癌症类型疾病特异性死亡的风险。将药物使用作为时间依赖变量进行分析,以最大限度地减少不朽时间偏倚。1年,2年和3年lag-time analyses.ResultsDuring中位随访时间为17.2年,共有27,233人死亡,其中8033人与癌症的主要死因。总共有32,628名男性(43%)使用抗凝剂。与不使用抗凝剂者相比,任何抗凝剂使用均与癌症死亡风险增加相关(HR=2.50,95% CI 2.37-2.64)。风险与使用量、持续时间或强度无关。在华法林和LMWH使用者中均观察到风险增加,尽管华法林使用者的风险没有那么强。此外,在所有抗凝剂category.ConclusionOur研究中,癌症特异性死亡风险与整体癌症死亡率相似,不支持抗凝剂使用者癌症死亡率降低。未来关于药物使用和癌症死亡率的研究应针对抗凝剂进行调整,因为抗凝剂与癌症死亡风险显著升高相关。
PurposeAnticoagulants may reduce mortality of cancer patients, though the evidence remains controversial. We studied the association between different anticoagulants and cancer death.MethodsAll anticoagulant use during 1995-2015 was analyzed among 75,336 men in the Finnish Randomized Study of Screening for Prostate Cancer. Men with prevalent cancer were excluded. Multivariable Cox regression was performed to compare risk of death from any cancer and disease-specific death from 9 specific cancer types between (1) anticoagulant users overall and (2) warfarin users compared to anticoagulant non-users and (3) warfarin or (4) low-molecular-weight heparins (LMWH) compared to users of other anticoagulants. Medication use was analyzed as time-dependent variable to minimize immortal time bias. 1-, 2- and 3-year lag-time analyses were performed.ResultsDuring a median follow-up of 17.2years, a total of 27,233 men died of whom 8033 with cancer as the primary cause of death. In total, 32,628 men (43%) used anticoagulants. Any anticoagulant use was associated with an increased risk of cancer death (HR=2.50, 95% CI 2.37-2.64) compared to non-users. Risk was similar independent of the amount, duration, or intensity of use. The risk increase was observed both among warfarin and LMWH users, although not as strong in warfarin users. Additionally, cancer-specific risks of death were similar to overall cancer mortality in all anticoagulant categories.ConclusionOur study does not support reduced cancer mortality among anticoagulant users. Future studies on drug use and cancer mortality should be adjusted for anticoagulants as they are associated with significantly higher risk of cancer death.